Free Trial

Cabaletta Bio (CABA) Stock Price, News & Analysis

Cabaletta Bio logo
$3.71
+0.16 (+4.51%)
(As of 11/1/2024 ET)

About Cabaletta Bio Stock (NASDAQ:CABA)

Key Stats

Today's Range
$3.49
$3.79
50-Day Range
$3.55
$5.97
52-Week Range
$3.47
$26.35
Volume
1.10 million shs
Average Volume
1.09 million shs
Market Capitalization
$181.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.10
Consensus Rating
Buy

Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
50th Percentile Overall Score

CABA MarketRank™: 

Cabaletta Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 601st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cabaletta Bio has only been the subject of 4 research reports in the past 90 days.

  • Read more about Cabaletta Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.28) to ($2.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cabaletta Bio is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cabaletta Bio is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cabaletta Bio has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cabaletta Bio's valuation and earnings.
  • Percentage of Shares Shorted

    7.74% of the outstanding shares of Cabaletta Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently decreased by 28.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cabaletta Bio does not currently pay a dividend.

  • Dividend Growth

    Cabaletta Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.74% of the outstanding shares of Cabaletta Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently decreased by 28.95%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cabaletta Bio has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

CABA Stock Analysis - Frequently Asked Questions

Cabaletta Bio's stock was trading at $22.70 on January 1st, 2024. Since then, CABA shares have decreased by 83.7% and is now trading at $3.71.
View the best growth stocks for 2024 here
.

Cabaletta Bio, Inc. (NASDAQ:CABA) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.01.

Cabaletta Bio (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.

Cabaletta Bio's top institutional investors include SG Americas Securities LLC (0.07%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Steven Nichtberger, Anup Marda, Gwendolyn Binder and Catherine Bollard.
View institutional ownership trends
.

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

Last Earnings
8/08/2024
Today
11/02/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CABA
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.10
High Stock Price Target
$50.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+657.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-67,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.51 per share

Miscellaneous

Free Float
44,023,000
Market Cap
$181.23 million
Optionable
Optionable
Beta
2.39
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CABA) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners